Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, brentuximab vedotin (Adcetris®) cannot be endorsed for use within NHS Wales for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD). |
||
|
||
Medicine details |
||
| Medicine name | brentuximab vedotin (Adcetris®) | |
| Formulation | 50 mg powder for concentrate for solution for infusion | |
| Reference number | 2074 | |
| Indication | Adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) |
|
| Company | Takeda UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 11/06/2019 | |